Form 4: Corcept Therapeutics Director Acquires Stock Options

Director Gregg H. Alton of Corcept Therapeutics acquired 12,500 stock options with an exercise price of $59.69, vesting over one year.

Summary

• Gregg H. Alton, a Director at Corcept Therapeutics, was granted 12,500 stock options on May 21, 2026.
• The options have an exercise price of $59.69 per share.
• These options are exercisable ratably in equal monthly installments over a one-year period, starting from May 21, 2026.
• Vesting is contingent upon Mr. Alton's continued service to the company on each monthly vesting date.
• The underlying securities are 12,500 shares of Corcept Therapeutics' common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation grant to a director rather than a significant financial event or strategic shift.

Positives

• Director Gregg H. Alton has acquired a significant number of stock options, indicating a commitment to the company's future performance.
• The stock options are exercisable, providing a potential future financial benefit to the director.
• The grant of options aligns the director's interests with those of shareholders through potential equity appreciation.

Negatives

• The acquisition of options is a forward-looking grant and does not represent immediate realized value.
• The exercise price of $59.69 suggests an expectation of stock price appreciation from current levels for the options to be profitable.

Risks

• The vesting of options is contingent on continued service, meaning any departure from the company before vesting completion would result in forfeiture.
• The value of the options is subject to market fluctuations and the company's future stock performance.

Future Outlook

The stock options granted to Director Gregg H. Alton vest over one year, subject to continued service, with an expiration date of May 21, 2036. This indicates a long-term incentive tied to the company's performance.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder value creation and long-term company growth.

Stakeholder Impact

• Shareholders: The alignment of director incentives with stock performance can be viewed positively, potentially leading to decisions that benefit shareholder value.
• Employees: Standard compensation practices for directors can contribute to overall company morale and perceived fairness in executive compensation structures.
• Management: The grant reinforces the importance of continued service and performance for executive compensation.

Next Steps

• Director Gregg H. Alton will continue to serve the company, with options vesting monthly over the next year.
• The company's stock performance will determine the ultimate value of these options upon exercise.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Stock Options, Director Compensation, Insider Trading, Securities, Equity